Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label, active comparator, 2-arm, prospective study to assess the glycosphingolipid clearance and clinical benefits of agalsidase beta (Fabrazyme) in male patients with classic Fabry disease switching from migalastat (Galafold)

Next Previous
Trial Profile

A randomized, open-label, active comparator, 2-arm, prospective study to assess the glycosphingolipid clearance and clinical benefits of agalsidase beta (Fabrazyme) in male patients with classic Fabry disease switching from migalastat (Galafold)

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Agalsidase beta (Primary) ; Migalastat
  • Indications Fabry's disease
  • Focus Therapeutic Use
  • Acronyms BCLEAR2
  • Sponsors Sanofi

Most Recent Events

  • 16 Oct 2021 Status changed from recruiting to discontinued.
  • 24 Dec 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top